<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04662125</url>
  </required_header>
  <id_info>
    <org_study_id>6324</org_study_id>
    <nct_id>NCT04662125</nct_id>
  </id_info>
  <brief_title>Management of Post Dural Pucture Headache After Lower Limb Surgeries: Oral Prednisolone vs Oral Pregabalin</brief_title>
  <official_title>Comparative Study Between Analgesic Effect of Oral Prednisolone and Oral Pregabalin in Management of Post-dural Puncture Headache in Patients Undergoing Lower Limb Surgeries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare between oral prednisolone and oral pregabalin in&#xD;
      management of PDPH to detect effectiveness of the treatment in reducing severity of PDPH,&#xD;
      total rescue analgesic consumption and adverse effects of prednisolone and pregabalin in&#xD;
      patients undergoing lower limb surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To compare between oral prednisolone and oral pregabalin in reducing severity post-dural&#xD;
           puncture headache after spinal anesthesia in patients undergoing lower limb surgeries.&#xD;
&#xD;
        2. To calculate total amount of postoperative analgesic requirement for 72 hours after the&#xD;
           onset of the headache in all patient groups.&#xD;
&#xD;
        3. To detect any side effects of the study medications in all patient groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2020</start_date>
  <completion_date type="Anticipated">July 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Analgesic management of post dural puncture headache: oral prednisolone vs oral pregabalin</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>anesthetist not sharing in the study will assess patient</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>pain intensity of headache</measure>
    <time_frame>From onset of the headache (0 hour).</time_frame>
    <description>measured by Visual Analogue Scale (VAS) on 0-10 cm scale (0-1 no headache, 2-4 mild headache, 5-7 moderate headache and 8-10 sever headache)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain intensity of headache</measure>
    <time_frame>at 12 hours</time_frame>
    <description>measured by Visual Analogue Scale (VAS) on 0-10 cm scale (0-1 no headache, 2-4 mild headache, 5-7 moderate headache and 8-10 sever headache)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain intensity of headache</measure>
    <time_frame>at 24 hours</time_frame>
    <description>measured by Visual Analogue Scale (VAS) on 0-10 cm scale (0-1 no headache, 2-4 mild headache, 5-7 moderate headache and 8-10 sever headache)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain intensity of headache</measure>
    <time_frame>at 48 hours</time_frame>
    <description>measured by Visual Analogue Scale (VAS) on 0-10 cm scale (0-1 no headache, 2-4 mild headache, 5-7 moderate headache and 8-10 sever headache)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pain intensity of headache</measure>
    <time_frame>at 72 hours</time_frame>
    <description>measured by Visual Analogue Scale (VAS) on 0-10 cm scale (0-1 no headache, 2-4 mild headache, 5-7 moderate headache and 8-10 sever headache)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total dose of rescue analgesia (ketorolac) consumption</measure>
    <time_frame>from the onset of headache till 72 hours</time_frame>
    <description>total consumption of rescue analgesia (ketorolac) from the onset of headache till 72 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>time of relieve of Post dural puncture headache</measure>
    <time_frame>from the onset of headache till 72 hours</time_frame>
    <description>time from start treatment till relieve symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of participant with nausea, vomiting, diplopia, dizziness and neck stiffness</measure>
    <time_frame>for 72 hours</time_frame>
    <description>The number of participant who has symptoms of post dural pucture headache as nausea, vomiting, diplopia, dizziness and neck stiffness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects of the study drugs e.g. sedation, blurred vision, sleepiness, and dizziness</measure>
    <time_frame>for 72 hours</time_frame>
    <description>In case of sedation, the level will be assessed by using Ramsay Sedation Score (1= anxious or agitated, 2= cooperative and oriented, 3= responds to commands only and 4= brisk response to light tap or loud auditory stimulus)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A (conservative treatment): Patients will receive good hydration, recumbent positioning, three tablets per day (combined paracetamol and caffeine tablet) for three days and stool softener.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B (oral prednisolone): Patients will receive three tablets per day (one oral tablet prednisolone 20 mg plus two tablets of vitamins to maintain blinding) for three days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group C (oral pregabalin): Patients will receive three tablets per day (oral tablet pregabalin 100 mg) for three days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral prednisolone</intervention_name>
    <description>Patients will receive three tablets per day (one oral tablet prednisolone 20 mg plus two tablets of vitamins to maintain blinding) for three days.</description>
    <arm_group_label>group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral Pregabalin</intervention_name>
    <description>Patients will receive three tablets per day (oral tablet pregabalin 100 mg) for three days.</description>
    <arm_group_label>group C</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>caffeine, paracetamol tablet</intervention_name>
    <description>Patients will receive good hydration, recumbent positioning, three tablets per day (combined paracetamol and caffeine tablet) for three days and stool softener.</description>
    <arm_group_label>group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - Both gender.&#xD;
&#xD;
          -  Age: 18- 50 years old.&#xD;
&#xD;
          -  American Society of Anesthesiologist (ASA) physical status I - II.&#xD;
&#xD;
          -  Patients are diagnosed as PDPH according to criteria of International Headache Society&#xD;
             (IHS) after lower limb surgeries .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Allergy to study drugs.&#xD;
&#xD;
          -  History of chronic headache and migraine.&#xD;
&#xD;
          -  History of cerebrovascular accidents and neurological disorders.&#xD;
&#xD;
          -  Systemic infection&#xD;
&#xD;
          -  History of uncontrolled DM or hepatic disease or pregnant female&#xD;
&#xD;
          -  Patient refusal or uncooperative patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dina Salem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>faculty of medicine , Zagazig university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dina Salem, MD</last_name>
    <phone>01099333513</phone>
    <phone_ext>002</phone_ext>
    <email>dinamaghraby@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>faculty of medicine, Zagazig university</name>
      <address>
        <city>Zagazig</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dina Salem, MD</last_name>
      <phone>01099333513</phone>
      <phone_ext>002</phone_ext>
      <email>dinamaghraby@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 28, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>April 4, 2021</last_update_submitted>
  <last_update_submitted_qc>April 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Dina Abdelhameed Elsadek Salem</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>oral prednisolone</keyword>
  <keyword>oral pregabalin</keyword>
  <keyword>post dural puncture headache (PDPH)</keyword>
  <keyword>lower limb surgeries</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Post-Dural Puncture Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

